Literature DB >> 25184272

Cancer metabolism as a therapeutic target: finding the right target(s) in the context of tumor heterogeneity, evolution, and metabolic plasticity.

Maria Laura Avantaggiati.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 25184272      PMCID： PMC4172372     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  14 in total

1.  13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression.

Authors:  Simon Hu; Asha Balakrishnan; Robert A Bok; Brittany Anderton; Peder E Z Larson; Sarah J Nelson; John Kurhanewicz; Daniel B Vigneron; Andrei Goga
Journal:  Cell Metab       Date:  2011-07-06       Impact factor: 27.287

Review 2.  Investigating metformin for cancer prevention and treatment: the end of the beginning.

Authors:  Michael N Pollak
Journal:  Cancer Discov       Date:  2012-08-27       Impact factor: 39.397

3.  Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis.

Authors:  Li Ma; Yongzhen Tao; Angeles Duran; Victoria Llado; Anita Galvez; Jennifer F Barger; Elias A Castilla; Jing Chen; Tomoko Yajima; Aleksey Porollo; Mario Medvedovic; Laurence M Brill; David R Plas; Stefan J Riedl; Michael Leitges; Maria T Diaz-Meco; Adam D Richardson; Jorge Moscat
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

Review 4.  Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

Authors:  R J Stevens; R Ali; C R Bankhead; M A Bethel; B J Cairns; R P Camisasca; F L Crowe; A J Farmer; S Harrison; J A Hirst; P Home; S E Kahn; J H McLellan; R Perera; A Plüddemann; A Ramachandran; N W Roberts; P W Rose; A Schweizer; G Viberti; R R Holman
Journal:  Diabetologia       Date:  2012-08-10       Impact factor: 10.122

5.  Intensive glucose control and risk of cancer in patients with type 2 diabetes.

Authors:  G Stefansdottir; S Zoungas; J Chalmers; A P Kengne; M J Knol; H G M Leufkens; A Patel; M Woodward; D E Grobbee; M L De Bruin
Journal:  Diabetologia       Date:  2011-04-21       Impact factor: 10.122

Review 6.  Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.

Authors:  Begoña Martin-Castillo; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Javier A Menendez
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

7.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

8.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Authors:  C J Currie; C D Poole; E A M Gale
Journal:  Diabetologia       Date:  2009-07-02       Impact factor: 10.122

9.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.

Authors:  Heather A Hirsch; Dimitrios Iliopoulos; Philip N Tsichlis; Kevin Struhl
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

10.  The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis.

Authors:  Olga Catalina-Rodriguez; Vamsi K Kolukula; York Tomita; Anju Preet; Ferdinando Palmieri; Anton Wellstein; Stephen Byers; Amato J Giaccia; Eric Glasgow; Chris Albanese; Maria Laura Avantaggiati
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.